A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†-Reference-Cited by-同舟云学术

A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†

Published:2014-06-07 Issue:12 Volume:16 Page:1661-1668
ISSN:1523-5866
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Su Jack M.,Thompson Patrick,Adesina Adekunle,Li Xiao-Nan,Kilburn Lindsay,Onar-Thomas Arzu,Kocak Mehmet,Chyla Brenda,McKeegan Evelyn,Warren Katherine E.,Goldman Stewart,Pollack Ian F.,Fouladi Maryam,Chen Alice,Giranda Vincent,Boyett James,Kun Larry,Blaney Susan M.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Clinical Neurology,Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/16/12/1661/16861523/nou103.pdf

Reference37 articles.

1. The role of double-strand break repair—insights from human genetics;O'Driscoll;Nat Rev Genet,2006

2. Molecular views of recombination proteins and their control;West;Nat Rev Mol Cell Biol,2003

3. PARP inhibition: PARP1 and beyond;Rouleau;Nat Rev Cancer,2010

4. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells;de Murcia;Proc Natl Acad Sci U S A,1997

5. Stimulation of the DNA-dependent protein kinase by poly(ADP-ribose) polymerase;Ruscetti;J Biol Chem,1998

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors;Cancer Medicine;2024-07

2. Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival;Cell Communication and Signaling;2023-11-16

3. Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma;Science Translational Medicine;2023-11

4. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration;European Journal of Cancer;2023-09

5. Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges;Targeting the DNA Damage Response for Cancer Therapy;2023